Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia

Executive Summary

• Tilray Medical announced its largest portfolio expansion to date in Australia, adding new medical‑cannabis products under the Redecan and Good Supply brands.
• The expanded offering includes flower, extracts, vapes, pastilles and high‑potency flower, increasing patient access across multiple formats.
• The launch underscores Tilrow’s long‑term strategic commitment to the Australian market and its broader international growth strategy.

Key Details

• Geographic focus: Australia (Tilray Medical Australia) – expansion to be rolled out over the coming months.
• Product lines added:
• Redecan brand: medical cannabis flower, extracts, vaporizers, pastilles.
• Good Supply brand: new high‑potency medical cannabis flower offerings.
• Strategic rationale: Aligns with rising demand in Australia’s regulated medical system and supports Tilray’s commitment to reliable, compliant supply of pharmaceutical‑grade cannabis.
• Leadership comment: Rajnish Ohri, President, International, Tilray Brands, highlighted the expansion as a “milestone” reflecting long‑term investment in priority global markets and enhanced patient access.
• Operational context: Tilray Medical already supplies EU‑GMP certified medical cannabis in Australia through established prescriber, pharmacy, and clinical distribution channels.

Notable Quotes

“Australia represents an important strategic market within our international growth strategy… This launch reflects our long‑term commitment to delivering quality, differentiated cannabis products.” – Rajnish Ohri, President, International, Tilray Brands

All boilerplate, forward‑looking statements and company background have been omitted for brevity.